These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33714536)

  • 1. Corrigendum to "Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy" [Radiother Oncol 150 (2020) 114-120].
    Chen D; Patel RR; Verma V; Ramapriyan R; Barsoumian HB; Angelica Cortez M; Welsh JW
    Radiother Oncol; 2021 May; 158():332-334. PubMed ID: 33714536
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy.
    Chen D; Patel RR; Verma V; Ramapriyan R; Barsoumian HB; Cortez MA; Welsh JW
    Radiother Oncol; 2020 Sep; 150():114-120. PubMed ID: 32525003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Geometric uncertainties in voluntary deep inspiration breath hold radiotherapy for locally advanced lung cancer" [Radiother. Oncol. 118 (2016) 510-514].
    Josipovic M; Persson GF; Dueck J; Peter Bangsgaard J; Westman G; Specht L; Aznar MC
    Radiother Oncol; 2019 Apr; 133():230. PubMed ID: 30773227
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" [Radiother. Oncol. 187 (2023) 109839].
    Kubeczko M; Jarząb M; Gabryś D; Krzywon A; Cortez AJ; Xu AJ
    Radiother Oncol; 2024 May; 194():110188. PubMed ID: 38447357
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Interaction between CIEDs and modern radiotherapy techniques: Flattening filter free-VMAT, dose-rate effects, scatter radiation, and neutron-generating energies" [Radiother Oncol 152 (2020) 196-202].
    Gauter-Fleckenstein B; Nguyen J; Jahnke L; Gaiser T; Rudic B; Büttner S; Wenz F; Borggrefe M; Tülümen E
    Radiother Oncol; 2021 Jan; 154():291. PubMed ID: 33460982
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharynx cancer: A multi-centre study" [Radiother. Oncol. 172 (2022) 111-117].
    Price JM; West CM; Dixon LM; Iyizoba-Ebozue Z; Garcez K; Lee LW; McPartlin A; Williams G; Slevin F; Sykes A; Prestwich RJD; Thomson DJ
    Radiother Oncol; 2022 Dec; 177():163. PubMed ID: 36395551
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272].
    López Torrecilla J; Hervás A; Zapatero A; Gómez Caamaño A; Macías V; Herruzo I; Maldonado X; Gómez Iturriaga A; Casas F; González San Segundo C
    Rep Pract Oncol Radiother; 2016; 21(1):90-2. PubMed ID: 26900365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum to "Master protocol trial design for technical feasibility of MR-guided radiotherapy" [Radiother. Oncol. 166 (2022) 33-36].
    Couwenberg A; Van der Heide U; Janssen T; Van Triest B; Remeijer P; Marijnen C; Sonke JJ; Nowee M
    Radiother Oncol; 2023 Jul; 184():109693. PubMed ID: 37207559
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas" [Radiother. Oncol. 158 (2021) 33-39].
    Lansu J; van Houdt WJ; van Langevelde K; van den Ende PLA; van der Graaf WTA; Schrage Y; van Boven H; Scholten AN; Haas RL
    Radiother Oncol; 2021 Oct; 163():245. PubMed ID: 34243980
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimising Radiation Therapy Dose to the Swallowing Organs at Risk: An In Silico Study of feasibility for Patients with Oropharyngeal Tumours.
    Barnhart MK; Cartmill B; Ward EC; Brown E; Sim J; Saade G; Rayner S; Robinson RA; Simms VA; Smee RI
    Dysphagia; 2019 Dec; 34(6):869-878. PubMed ID: 30741335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality assurance in radiation oncology. A study of feasibility and impact on action levels of an in vivo dosimetry program during breast cancer irradiation.
    Cozzi L; Fogliata-Cozzi A
    Radiother Oncol; 1998 Apr; 47(1):29-36. PubMed ID: 9632289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77].
    Putora PM; Glatzer M; De Ruysscher D; Faivre-Finn C; Belderbos J; Besse B; Blackhall F; Califano R; Cappuzzo F; de Marinis F; Dziadiuszko R; Felip E; Früh M; Garrido P; Le Pechoux C; McDonald F; Nestle U; Novello S; O' Brien M; Paz Ares L; Peeters S; Pöttgen C; Ramella S; Reck M; Troost EGC; Van Houtte P; Westeel V; Widder J; Mornex F; Slotman BJ
    Radiother Oncol; 2019 Dec; 141():332. PubMed ID: 31810511
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77].
    Brand TM; Iida M; Luthar N; Starr MM; Huppert EJ; Wheeler DL
    Radiother Oncol; 2019 Jan; 130():195. PubMed ID: 30442378
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Biological effective dose is associated with radiological toxicity after lung stereotactic ablative radiation therapy" [Radiother. Oncol. 183 (2023) 109552].
    Cases C; Benegas M; Sánchez M; Vollmer I; Casas F; Gomà C; Mollà M
    Radiother Oncol; 2023 Sep; 186():109776. PubMed ID: 37423000
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer.
    Cho Y; Park S; Byun HK; Lee CG; Cho J; Hong MH; Kim HR; Cho BC; Kim S; Park J; Yoon HI
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1065-1073. PubMed ID: 31476418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to: "BMI1-KLF4 axis deficiency improves responses to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer" [Radiother Oncol 149 (2020) 249-258].
    Hsu YC; Luo CW; Huang WL; Wu CC; Chou CL; Chen CI; Chang SJ; Chai CY; Wang HC; Chen TY; Li CF; Pan MR
    Radiother Oncol; 2021 Oct; 163():247-248. PubMed ID: 34344522
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients" [Radiother Oncol 156 (2021) 127-135].
    Bosma SCJ; Hoogstraat M; van Werkhoven E; de Maaker M; van der Leij F; Elkhuizen PHM; Fourquet A; Poortmans P; Boersma LJ; Bartelink H; van de Vijver MJ;
    Radiother Oncol; 2021 Oct; 163():244. PubMed ID: 34120786
    [No Abstract]   [Full Text] [Related]  

  • 18. Correlation between dose subfractions: in regard to Tome et al. [Radiother Oncol 2004;72:113-114].
    Wang JZ; Mayr NA; Yuh WT
    Radiother Oncol; 2005 Mar; 74(3):347-8. PubMed ID: 15763319
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Contiguous pattern spreading in patients with Hodgkin's disease" [Radiother. Oncol. 47 (1998) 7-16].
    Ludwig Roth S
    Radiother Oncol; 2020 Jun; 147():99. PubMed ID: 32259752
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Dose painting by numbers based on retrospectively determined recurrence probabilities" [Radiother Oncol 122 (2017) 236-241].
    Grönlund E; Johansson S; Montelius A; Ahnesjö A
    Radiother Oncol; 2019 Feb; 131():243. PubMed ID: 30563693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.